ALS clinical trials
- 11 October 2011
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 77 (15), 1432-1437
- https://doi.org/10.1212/wnl.0b013e318232ab9b
Abstract
Objective: To evaluate efficacy and safety of clobazam, a 1,5-benzodiazepine, as adjunctive therapy for Lennox-Gastaut syndrome (LGS). Methods: Patients aged 2–60 years were randomized to placebo or clobazam 0.25, 0.5, or 1.0 mg/kg/day. Study consisted of 4-week baseline, 3-week titration, and 12-week maintenance phases, followed by a 2- or 3-week taper or continuation in an open-label extension. Primary endpoint was percentage decrease in mean weekly drop seizure rates during maintenance vs baseline phases for modified intention-to-treat (mITT) population. Secondary outcomes included other seizure types, responder rates, and physicians' and caregivers' global assessments. Results: A total of 305 patients were screened, 238 were randomized, and 217 composed the mITT population. Of patients enrolled after a protocol amendment, 125/157 (79.6%) completed. Average weekly drop seizure rates decreased 12.1% for placebo vs 41.2% (p = 0.0120), 49.4% (p = 0.0015), and 68.3% (p < 0.0001) for the clobazam 0.25-, 0.5-, and 1.0-mg/kg/day groups. Responder rates (≥50%) were 31.6% (placebo) vs 43.4% (p = 0.3383), 58.6% (p = 0.0159), and 77.6% (p < 0.0001) for clobazam 0.25-, 0.5-, and 1.0-mg/kg/day groups. Physicians' and caregivers' assessments indicated clobazam significantly improved symptoms. Somnolence, pyrexia, upper respiratory infections, and lethargy were the most frequent adverse events reported for clobazam. Conclusions: Clobazam significantly decreased weekly drop seizure rates in LGS. No new safety signals were identified. Classification of evidence: This study provides Class II evidence that clobazam as adjunctive therapy is efficacious, in a dosage-dependent manner, in reducing mean weekly drop seizure rates of patients with LGS over 12 weeks.This publication has 24 references indexed in Scilit:
- Repeated courses of granulocyte colony‐stimulating factor in amyotrophic lateral sclerosis: Clinical and biological results from a prospective multicenter studyMuscle & Nerve, 2011
- The epidemiology and treatment of ALS: Focus on the heterogeneity of the disease and critical appraisal of therapeutic trialsAmyotrophic Lateral Sclerosis, 2010
- Tracheostomy in amyotrophic lateral sclerosis: a 10-year population-based study in ItalyJournal of Neurology, Neurosurgery & Psychiatry, 2010
- The neurobiology of amyotrophic lateral sclerosisEuropean Journal of Neuroscience, 2010
- Quality control of vital capacity as a primary outcome measure during phase III therapeutic clinical trial in amyotrophic lateral sclerosisAmyotrophic Lateral Sclerosis, 2010
- Why have we failed to achieve neuroprotection in Parkinson's disease?Annals of Neurology, 2009
- Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: A double- blind, randomized, multicentre, placebo-controlled trialAmyotrophic Lateral Sclerosis, 2009
- Epidemiology and clinical features of amyotrophic lateral sclerosis in Ireland between 1995 and 2004Journal of Neurology, Neurosurgery & Psychiatry, 2008
- Population Issues in Clinical TrialsProceedings of the American Thoracic Society, 2007
- Positive effects of tertiary centres for amyotrophic lateral sclerosis on outcome and use of hospital facilitiesJournal of Neurology, Neurosurgery & Psychiatry, 2006